• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Neuronetics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    7/30/24 8:52:30 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care
    Get the next $STIM alert in real time by email
    8-K
    false 0001227636 0001227636 2024-07-25 2024-07-25

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported) July 25, 2024

     

     

    NEURONETICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-38546   33-1051425

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    3222 Phoenixville Pike, Malvern, PA   19355
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code (610) 640-4202

     

    (Former name or former address, if changed since last report.) Not applicable.

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol (s)

     

    Name on each exchange
    on which registered

    Common Stock ($0.01 par value)   STIM   The Nasdaq Global Market

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 1.01

    Entry into a Material Definitive Agreement.

    On July 25, 2024, Neuronetics, Inc. (the “Company”) entered into a Credit Agreement and Guaranty with Perceptive Credit Holdings IV, LP, (“Perceptive”) as collateral agent and other lenders defined in the agreement (the “Perceptive Facility”) that replaced the Company’s previous $60.0 million credit facility with SLR Investment Corp. (formerly known as Solar Capital Ltd.) (“Solar”, and such facility, the “Solar Facility”).

    The Perceptive Facility permits the Company to borrow up to an aggregate amount of $90.0 million in three tranches of term loans, a “Tranche 1 Loan”, a “Trance 2 Loan” and a “Tranche 3 Loan.” On July 25, 2024, the Company borrowed an aggregate amount of $50.0 million, which was the aggregate amount available under the Tranche 1 Loan portion of the Perceptive Facility. Under the Tranche 2 Loan portion of the Perceptive Facility, the Company is permitted to borrow, at its election, up to an aggregate amount of $15.0 million, (i) upon the Company achieving a specified amount of trailing twelve months net revenue, and (ii) assuming there has been no event of default under the Perceptive Facility prior to such election. The Tranche 2 Loan portion of the Perceptive Facility must be borrowed on or before December 31, 2025. Under the Tranche 3 Loan portion of the Perceptive Facility, the Company may request to borrow, at the consent of the Majority Lenders (as defined in the Perceptive Facility), up to an aggregate amount of $25.0 million. The Tranche 3 Loan portion of the Perceptive Facility must be borrowed on or before June 30, 2026. All amounts borrowed under the Perceptive Facility are due on July 25, 2029.

    Each of the Tranche 1 Loan, Tranche 2 Loan and Tranche 3 Loan accrues interest from the date of borrowing through the date of repayment at a floating per annum rate of interest equal to the sum of 7.00% plus the greater of (a) 4.50% and (b) One-Month Term SOFR (as defined in the Perceptive Facility). There will be no scheduled repayments of the principal on the Tranche 1 Loan, Tranche 2 Loan and Tranche 3 Loan prior to the maturity date.

    If the Company prepays either the Tranche 1 Loan, Tranche 2 Loan or Tranche 3 Loan prior to their scheduled maturity date, the Company will also be required to pay prepayment fees to Perceptive equal to 6% of the principal amount of such term loan then-prepaid if prepaid on or before the first anniversary of the closing date, 5% of the principal amount of such term loan then-prepaid if prepaid after the first anniversary and on or before the second anniversary of the closing date, 4% of the principal amount of such term loan then-prepaid if prepaid after the second anniversary and on or before the third anniversary of the closing date, and 3% of the principal amount of such term loan then-prepaid if prepaid after the third anniversary and on or before the fourth anniversary of the closing date.

    The Company’s obligations under the credit facility are secured by a first priority security interest in substantially all of its assets, including its intellectual property. The Perceptive Facility requires the Company to comply with certain financial covenants as well as customary affirmative and negative covenants.

     


    The Perceptive Facility related to the credit facility contains events of default, including, without limitation, events of default upon: (i) failure to make payment pursuant to the terms of the agreement; (ii) violation of covenants; (iii) material adverse changes to the Company’s business; (iv) insolvency; (v) material cross-defaults; (vi) significant judgments, orders or decrees for payments by the Company; (vii) incorrectness of representations and warranties; (viii) significant adverse ERISA events; (ix) failure by the Company to be registered with the United States Securities and Exchange Commission in good standing; and (x) failure by the Company to maintain a valid and perfected lien on the collateral securing the borrowing.

    As consideration for the Perceptive Facility, the Company agreed to issue to Perceptive warrants to purchase up to 1,462,500 shares of the Company’s common stock, with a warrant exercisable into 1,125,000 shares of the Company’s common stock issued on the closing date (the “Initial Warrant”). The per share exercise price for the Initial Warrant is equal to the lower of (x) the 10-day volume weighted average price of the Company’s common stock on the business day immediately prior to the closing date and (y) the 10-day volume weighted average price of the common stock ended on August 31, 2024. In addition to the Initial Warrant, an additional warrant will be issued for 337,500 shares of common stock concurrently with the borrowing of the Tranche 2 Loan. The per share exercise price for the additional warrant will be equal to the exercise price of the Initial Warrant. Each warrant will be exercisable, in whole or in part, until the tenth anniversary of the applicable date of issuance.

    The foregoing summary description of the Perceptive Facility for the Perceptive Facility and the Perceptive Facility does not purport to be complete and is qualified in its entirety by reference to the credit agreement for the Perceptive Facility, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

     

    Item 1.02.

    Termination of a Material Definitive Agreement.

    Simultaneously with the Company’s entry into the Perceptive Facility, on July 25, 2024, the Company prepaid in full all outstanding obligations under, and terminated, its existing Loan and Security Agreement, dated as of March 2, 2020, as amended, with SLR Investment Corp. (formerly known as Solar Capital Ltd.) (“Solar”), as collateral agent, and the lenders listed on Schedule 1.1 thereto, for a credit facility (the “Solar Facility”). The material terms and conditions of the Solar Facility were described in the Company’s Current Reports on Form 8-K filed on March 3, 2020, December 8, 2020, February 22, 2022, April 4, 2023, October 3, 2023 and the Company’s Annual Report on Form 10-K filed on March 7, 2024 and such descriptions are incorporated herein by reference. In connection with this prepayment, the Company paid total consideration of approximately $64.643 million, which consisted of (i) $60.0 million of remaining principal amount outstanding, (ii) approximately $0.5 million of accrued and unpaid interest, (iii) $2.97 million in connection with the Fourth Amendment Final Fee, and (iv) $1.2 million in connection with a prepayment fee. The Company funded the repayment of the Solar Facility using a portion of the proceeds from the Perceptive Facility.

     

    Item 2.03.

    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

    The disclosure set forth in Item 1.01 of the Current Report on Form 8-K is hereby incorporated by reference.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    Number

      

    Description

     4.1    Form of Warrant
     4.2    Form of Note
     4.3    Form of Security Agreement
    10.1    Credit Agreement and Guaranty, dated July 25, 2024, by and among Neuronetics, Inc., as the borrower, certain Subsidiaries of Neuronetics, Inc. from time to time party thereto, as guarantors, the lenders from time to time party thereto, and PERCEPTIVE CREDIT HOLDINGS IV, LP, in its capacity as the administrative agent for the lenders
    99.1    Neuronetics Announces the Closing of up to $90 Million Senior Secured Credit Facility with Perceptive Advisors
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          NEURONETICS, INC.
          (Registrant)
    Date: July 30, 2024     By:  

    /s/ Stephen Furlong

        Name:   Stephen Furlong
        Title:   VP, Finance and Chief Financial Officer
          (Principal Financial and Accounting Officer)
    Get the next $STIM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STIM

    DatePrice TargetRatingAnalyst
    8/13/2024Outperform → Mkt Perform
    William Blair
    10/14/2021$18.00 → $12.00Market Outperform
    JMP Securities
    10/13/2021Outperform → Mkt Perform
    William Blair
    10/13/2021Buy → Neutral
    BTIG
    More analyst ratings

    $STIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CFO and Treasurer Pfanstiel Steven was granted 170,212 shares, increasing direct ownership by 43% to 570,212 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    12/31/25 5:05:03 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    EVP, GC, CCO and CS Macan William Andrew was granted 164,361 shares, increasing direct ownership by 31% to 691,166 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    12/31/25 5:05:04 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Director Cucuz Sasha was granted 6,410 shares, increasing direct ownership by 0.43% to 1,512,798 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    10/22/25 4:45:02 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cascella Robert bought $75,000 worth of shares (100,000 units at $0.75), increasing direct ownership by 28% to 453,098 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    9/13/24 5:02:03 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Director Muir Glenn P bought $20,000 worth of shares (25,000 units at $0.80), increasing direct ownership by 9% to 289,818 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    9/6/24 5:05:03 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Director Muir Glenn P bought $21,250 worth of shares (25,000 units at $0.85), increasing direct ownership by 10% to 264,818 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    8/30/24 5:15:02 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    SEC Filings

    View All

    Neuronetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Neuronetics, Inc. (0001227636) (Filer)

    2/10/26 5:09:09 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Neuronetics Inc.

    8-K - Neuronetics, Inc. (0001227636) (Filer)

    1/22/26 7:30:18 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Neuronetics Inc.

    8-K - Neuronetics, Inc. (0001227636) (Filer)

    1/6/26 5:00:25 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neuronetics downgraded by William Blair

    William Blair downgraded Neuronetics from Outperform to Mkt Perform

    8/13/24 10:26:16 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    JMP Securities reiterated coverage on Neuronetics with a new price target

    JMP Securities reiterated coverage of Neuronetics with a rating of Market Outperform and set a new price target of $12.00 from $18.00 previously

    10/14/21 8:41:45 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics downgraded by William Blair

    William Blair downgraded Neuronetics from Outperform to Mkt Perform

    10/13/21 12:25:53 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

    All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basisFull year 2025 revenue of $149.2 million, representing 99% year-over-year growth on an as reported basis and 15% year-over-year growth on an adjusted pro forma basisAchieved positive operating cash flow of $0.9 million in the fourth quarter 2025Ended 2025 with total cash of $34.1 million, inclusive of cash, cash equivalents and restricted cash MALVERN, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a verti

    2/10/26 4:34:49 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference

    MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec. 4, 2025. The fireside chat is scheduled at 12:30 p.m. (ET) the same day. The presentation will be available via the conference portal to registered attendees. About Neuronetics Neuronetics, Inc.

    11/20/25 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression

    MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, announced that TriWest, the regional administrator for TRICARE, has updated its medical policy to include TMS coverage for adolescents aged 15 and older. TRICARE coverage is primarily used by active and retired military service members and their eligible family members. This policy update, effective immediately, applies to TRICARE beneficiaries in the following states: Alaska, Arizona, Arkansas, C

    11/12/25 10:33:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Leadership Updates

    Live Leadership Updates

    View All

    Neuronetics Appoints New Chief Financial Officer

    Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process Neuronetics reiterates guidance for second quarter and full year 2025 MALVERN, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Steven Pfanstiel has been appointed as the company's new Chief Financial

    7/15/25 7:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

    MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) --  Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strate

    6/2/25 4:30:00 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

    Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

    7/12/23 9:00:00 AM ET
    $STIM
    $ABMD
    Medical/Dental Instruments
    Health Care

    $STIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuronetics Inc.

    SC 13D - Neuronetics, Inc. (0001227636) (Subject)

    12/17/24 9:15:11 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

    SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

    11/14/24 1:42:23 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

    SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

    11/14/24 11:17:47 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Financials

    Live finance-specific insights

    View All

    Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

    All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basisFull year 2025 revenue of $149.2 million, representing 99% year-over-year growth on an as reported basis and 15% year-over-year growth on an adjusted pro forma basisAchieved positive operating cash flow of $0.9 million in the fourth quarter 2025Ended 2025 with total cash of $34.1 million, inclusive of cash, cash equivalents and restricted cash MALVERN, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a verti

    2/10/26 4:34:49 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, the leading provider of Transcranial Magnetic Simulation (TMS), announced that it plans to release third quarter 2025 financial and operating results prior to market open on Tuesday, November 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-se

    10/21/25 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release second quarter 2025 financial and operating results prior to market open on Tuesday, August 5, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/d6qidqaw. To listen to the conference call on your telephone, participants may register for t

    7/22/25 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care